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Leicester, United Kingdom; and Hennigsdorf, Germany
Objectives Our aim was to assess the prognostic value of midregional proatrial natriuretic peptide (MR-proANP) in patients
after acute myocardial infarction (AMI).
Background Multimarker strategies may assist risk stratification after AMI. Midregional proatrial natriuretic peptide is a
newly described stable fragment of N-terminal proatrial natriuretic peptide. We compared the prognostic value
of MR-proANP and an established marker, N-terminal pro-B-type natriuretic peptide (NT-proBNP), after AMI.
Methods We recruited 983 consecutive post-AMI patients (720 men, median age 65 [range 24 to 95] years) in a prospec-
tive study with follow-up over 343 (range 0 to 764) days.
Results Plasma MR-proANP was raised in patients who died (n  101) compared with that seen in survivors (median
310 [range 48 to 1,150] pmol/l vs. 108 [range 4.9 to 1,210] pmol/l, p  0.0001). Using Cox modeling,
log10MR-proANP (hazard ratio 3.87) and log10NT-proBNP (hazard ratio 3.25) were significant independent predic-
tors of death. In patients stratified by NT-proBNP in the highest quartile (5,900 pmol/l), MR-proANP in the
top quartile (330 pmol/l) was associated with poorer outcome (p  0.0001). Findings were similar for heart
failure as an individual end point. However, neither marker predicted recurrent AMI.
Conclusions The A- and B-type natriuretic systems are activated after AMI. Midregional proatrial natriuretic peptide is a pow-
erful predictor of adverse outcome, especially in those with an elevated NT-proBNP. Midregional proatrial natri-
uretic peptide may represent a clinically useful marker of prognosis after an AMI as part of a multimarker strat-
egy targeting the natriuretic neurohormonal pathway. (J Am Coll Cardiol 2008;51:1857–64) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.041A
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008, accepted January 21, 2008.cute myocardial infarction (AMI) results as a consequence
f plaque rupture and superimposed thrombus formation.
his acute event leads to acute disruption of myocardial
ontractility and neurohormonal activation triggering the
elease of the natriuretic peptide hormones from the myo-
ardial tissues (1). The natriuretic peptide hormones atrial
atriuretic peptide (ANP) and B-type natriuretic peptide
BNP) and the amino-terminal fragments of their prohor-
ones (N-terminal [NT]-proANP and NT-proBNP, re-
pectively) have now been well established as predictors of
oor outcome in patients after AMI and in patients with
eart failure (HF) (2–7). The prognostic information pro-
ided by these hormones is over and above that of impaired
eft ventricular function, Killip class, and renal impairment
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The LAMP Study May 13, 2008:1857–64(6). Both hormones promote na-
triuresis and diuresis and have
vasodilator properties. The pro-
hormones have a larger molecu-
lar weight, lack binding interac-
tions with cells or other proteins
and receptors, and have longer
half-lives as there are no active
excretion pathways and may,
therefore, be easier to measure in
plasma. B-type natriuretic pep-
tide and its more stable counter-
part NT-proBNP have shown
the greatest promise in this area
(1) as their use covers a range of
acute coronary syndromes (8). A
multimarker approach looking
specifically at the natriuretic neu-
rohormones, however, may be
more beneficial. Previous studies
have investigated combinations
of BNP, NT-proBNP, ANP,
and N-terminal atrial natriuretic
peptide (N-ANP). Richards et
al. (5) proposed NT-proBNP as
the strongest independent
marker for death or HF, with no
additional contribution from
N-ANP. In the study of Omland
et al. (9) it was found that only
NP gave additional prognostic information on mortality
ver and above left ventricular systolic function. Our group
as previously directly compared N-ANP and NT-proBNP
nd found N-ANP may be of benefit in predicting late
ortality and NT-proBNP at predicting early mortality
10). Here we investigate midregional proatrial natriuretic
eptide (MR-proANP) in a multimarker approach. Epitopes
f the antibodies used in the assay for MR-proANP cover
mino acids 53 to 90 of N-terminal proatrial natriuretic
eptide proANP (11). Midregional epitopes of prohormones
ay be more stable to degradation by exoproteases, unlike
pitopes in the N- or C-terminals of proANP used in previous
mmunoassays. Previous studies may, therefore, have underes-
imated the utility of proANP as a biomarker. The diagnostic
se of MR-proANP has recently been described in the
ifferential diagnosis of acute decompensated HF, where it has
een shown to be comparable to that of BNP and NT-
roBNP (12). Our aim was to investigate whether MR-
roANP alone or in combination with NT-proBNP would be
f benefit in determining the prognosis after AMI, particularly
or death and HF. We were particularly interested to see if a
ultimarker approach using combined information from 2
atriuretic markers could give prognostic information over and
bove just NT-proBNP, a peptide of established prognostic
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
ANP  atrial natriuretic
peptide
AUC  area under the
curve(s)
BNP  B-type natriuretic
peptide
CI  confidence interval
CV  coefficient of
variation
eGFR  estimated
glomerular filtration rate
HF  heart failure
HR  hazard ratio
MI  myocardial infarction
MR-proANP  midregional
proatrial natriuretic peptide
NSTEMI  non–ST-segment
elevation myocardial
infarction
NT-proBNP  N-terminal
pro-B-type natriuretic
peptide
STEMI  ST-segment
elevation myocardial
infarctionalue benefit in this group of patients (5,10,13). aethods
tudy population. We studied 983 consecutive AMI pa-
ients admitted to the Coronary Care Unit of the Leicester
oyal Infirmary. Acute myocardial infarction was diagnosed
f a patient had a plasma creatine kinase-MB elevation
reater than twice normal or a cardiac troponin I level 0.1
g/ml with at least 1 of the following: chest pain lasting
20 min or diagnostic serial electrocardiographic changes
onsisting of new pathological Q waves or ST-segment and
-wave changes. Acute myocardial infarction was subcat-
gorized into ST-segment elevation myocardial infarction
STEMI) or non–ST-segment myocardial infarction
NSTEMI). The study complied with the Declaration of
elsinki and was approved by the local ethics committee;
ritten informed consent was obtained from all patients.
xclusion criteria were known malignancy, or surgery in the
revious month. The estimated glomerular filtration rate
eGFR) was calculated from the simplified formula derived
rom the MDRD (Modification of Diet in Renal Disease)
tudy, recently validated in patients with HF (14).
lasma samples. Blood samples were drawn on 1 occasion
to 5 days after the onset of chest pain for determination of
lasma MR-proANP and NT-proBNP. After 15-min bed
est, 20 ml blood was collected into tubes containing
thylenediaminetetraacetic acid and aprotinin. All plasma
as stored at 70°C until assayed in a blinded fashion in a
ingle batch. In a subgroup of 132 patients from the original
83-patient cohort, blood sampling was performed daily for
days from admission to discharge.
chocardiography. Transthoracic echocardiography was
erformed in patients using a Sonos 5500 instrument
Philips Medical Systems, Reigate, United Kingdom). Left
entricular ejection fraction was calculated using the biplane
ethod of discs formula (15).
T-proBNP assay. Our NT-proBNP assay was based on
noncompetitive assay as previously published (8). Sheep
ntibodies were raised to the N-terminus of human NT-
roBNP, and monoclonal mouse antibodies were raised to
he C-terminus. Samples or NT-proBNP standards were
ncubated in C-terminal immunoglobulin G–coated wells
ith the biotinylated N-terminal antibody for 24 h at 4°C.
etection was with methyl-acridinium-ester-labelled
treptavidin on a MLX plate luminometer (Dynex Tech-
ologies Ltd., Worthing, United Kingdom). The lower
imit of detection was 0.3 pmol/l. There was no cross
eactivity with ANP, BNP, or C-type natriuretic peptide.
R-proANP assay. Midregional proatrial natriuretic pep-
ide was detected using a novel commercial sandwich
mmunoassay in the chemiluminescence-coated tube-
ormat (BRAHMS AG) as described (11). Briefly, patient
amples (1:40 dilution of 5 l plasma in incubation buffer)
r standards were added in duplicate to antibody-coated
ubes (affinity purified sheep polyclonal antibodies directed
gainst proANP peptide 73 to 90) and incubated for 30 min
t room temperature. After 5 washes with 1 ml washing
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May 13, 2008:1857–64 The LAMP Studyuffer, 200 l tracer was added, containing acridinium
ster-labelled anti-proANP antibody (affinity purified sheep
olyclonal antibodies directed against proANP peptide 53
o 72), followed by 30 min incubation at room temperature.
ubes were washed 3 times with 1 ml washing buffer, and
etection was performed in a LB952T luminometer
Berthold, Bad Wildbad, Germany; 1 s detection time per
ample). Relative light units of the chemiluminescence assay
ere expressed in pmol/l MR-proANP, as calculated from
calibration curve (4 to 1,800 pmol/l) that was included in
very analytical run. The lower detection limit of the assay
s 4.3 pmol/l, and the functional sensitivity of the assay is 11
mol/l MR-proANP. The interassay coefficient of variation
CV) within the range of plasma measurements was under
0% (8.0% CV at 100 pmol/l; 6.5% CV at 400 pmol/l).
nd points. Our primary end point was death. We also
nvestigated hospitalization for HF and recurrent AMI as
ndividual secondary end points. Hospitalization for HF was
efined as a hospital readmission for which HF was the
rimary reason. Myocardial infarction (MI) was diagnosed
n established criteria as described in the preceding text
16). End points were obtained by reviewing the Office of
ational Statistics Registry and by contacting each patient.
here was a minimum 60-day follow-up of all surviving
atients.
tatistical analysis. Statistical analyses were performed on
PSS Version 14 (SPSS Inc., Chicago, Illinois). Compar-
sons of continuous variables were made using the Mann-
hitney U test. Comparisons in the daily sampling study
ere performed using the general linear model with re-
eated measures, with correction for multiple comparisons
sing the Bonferroni method. The general linear model
epeated measures procedure in SPSS provides analysis of
ariance when the same measurement is made several times
n each subject or case. Spearman’s correlations were
erformed. The relationship of baseline variables with death
nd HF was assessed using Cox proportional hazards
nalysis by univariate and multivariate analysis. Factors with
nivariate significance of a value of p 0.1 were included in
ultivariate analyses. Echocardiographic data were analyzed
n a substudy (see the following text). The Kaplan-Meier
umulative survival curves were constructed and compared
y the log-rank test and the log-rank test for trend.
ormality of continuous variables was assessed by the
olmogorov-Smirnov test. Levels of NT-proBNP and
R-proANP were normalized by log10 transformation.
hus, odds ratios and hazard ratios (HRs) refer to a 10-fold
ise in the levels of these markers. Hazard ratio and 95%
onfidence intervals (CIs) for risk factors and significance
evel for chi-square (likelihood ratio test) are given.
To compare the accuracy of NT-proBNP and MR-
roANP, receiver-operator characteristic curves were gen-
rated, and the area under the curve (AUC) was calculated.
2-tailed p value of 0.05 was deemed to be statistically
ignificant. The study size of 980 patients had a 90% power
t a value of p  0.01 to detect a difference of 0.63 in the
m
PR between the top quartile of the biomarker compared
ith the other quartiles.
esults
atient characteristics. Patient details are recorded in
able 1. Median length of follow-up was 343 (range 0 to
64) days. The minimum length of follow-up for survivors
as 60 days. During follow-up 101 (10.3%) patients died,
9 (5.0%) were readmitted with HF, and there were 79
8.0%) recurrent AMIs. One-year mortality was 18.1%.
here were 783 STEMI patients. No patient was lost to
ollow-up.
lasma profile of MR-proANP and NT-proBNP. In a
ubgroup of 132 patients (102 men, median age 64 [range
2 to 90] years), daily blood samples were obtained for 5
ays post-admission. Seven patients in the subgroup expe-
ienced the primary end point of death. The time course of
lasma NT-proBNP is shown in Figure 1. This shows
ignificant changes with day of sampling (p  0.001,
onferroni corrected for 4 comparisons in 132 patients),
ith peak levels on Day 2 (p  0.001 and 0.02 compared
ith Day 1 and Day 3, respectively, using the Bonferroni
orrection for 4 comparisons in 132 patients). For plasma
R-proANP, the peak was most evident on Day 1 (signif-
cantly elevated compared with Day 2, p  0.001 using the
onferroni correction for 4 comparisons in 132 patients),
alling on Day 2 before significantly rising again on Day 3
p  0.001, Bonferroni corrected for 4 comparisons in 132
atients).
R-proANP levels. Midregional proatrial natriuretic
eptide was raised in patients who died compared with that
n event-free survivors. There was no significant difference
haracteristics of Patients in the Study*
Table 1 Characteristics of Patients in the Study*
AMI Patients
Number 983
Age (yrs) 66 (24–95)
Male gender 720
eGFR (ml/min/1.73 m2 surface area) 68.4 (14.9–166.1)
NT-proBNP (pmol/l) 907.4 (0.3–28,886.8)
MR-proANP (pmol/l) 117.0 (4.9–1,210)
Previous medical history (%)
Angina pectoris 251 (25.5)
Myocardial infarction 165 (16.8)
Hypertension 430 (43.7)
Diabetes mellitus 213 (21.7)
Heart failure 57 (5.8)
Hypercholesterolemia 227 (23.1)
STEMI (%) 783 (79.7)
Revascularization (fibrinolysis) 580/783 (79.1)
Revascularization (PCI) 122 (12.4)
Cardiogenic shock 10 (1.0)
Current smokers/ex-smokers 617 (62.8)
Values are medians (range) or numbers (percentage).
AMI  acute myocardial infarction; eGFR  estimated glomerular filtration rate; MR-proANP 
idregional proatrial natriuretic peptide; NT-proBNP  N-terminal pro-B-type natriuretic peptide;
CI  percutaneous coronary intervention; STEMI  ST-segment elevation myocardial infarction.
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The LAMP Study May 13, 2008:1857–64n MR-proANP levels between anterior or other site of
MI, STEMI, versus NSTEMI. However, there was a
ignificantly higher level in female versus male patients,
atients with a prior history of AMI, patients with a prior
istory of hypertension, and patients who had a prior history of
F or diabetes, and higher levels in patients who were not
hrombolyzed. Midregional proatrial natriuretic peptide levels
ere higher in patients with Killip class above 1. Plasma
R-proANP correlated with age (rs  0.59, p  0.0005),
GFR (rs  0.54, p  0.0005), Killip class (rs  0.25, p 
.0005), and NT-proBNP (rs  0.63, p  0.0005) (Fig. 2).
here were some patients with markedly raised MR-proANP
ut low NT-proBNP levels. These patients had the same
emographic characteristics as the main cohort of patients
escribed but a significantly better eGFR. No difference in
utcomes was noted.
T-proBNP levels. Significant differences in NT-
Figure 1 Daily Peptide Sampling and Box Plots
(A) Patient plot for 60 patients. Changes in plasma midregional proatrial natriuret
individual patients within the first 5 days after acute myocardial infarction. (B) Mid
range of plasma peptide levels in the 132 patients with serial sampling data.roBNP levels were noted between male and female oatients; those with a Killip class above 1; and in patients
ith a prior history of HF, hypertension, AMI, or diabetes.
lasma NT-proBNP levels were also higher in STEMI versus
STEMI patients, and those with anterior site of AMI.
lasma NT-proBNP was correlated with age, eGFR, and
illip class. There were some patients with markedly raised
T-proBNP but low MR-proANP levels. These patients had
he same demographic characteristics as the main cohort of
atients described but a significantly worse eGFR. No differ-
nce in outcomes was noted.
rimary end points: MR-proANP and NT-proBNP as
redictors of death. When clinical characteristics were en-
ered into a Cox proportional hazards model (Table 2),
R-proANP (HR 3.87) and NT-proBNP (HR 3.25) to-
ether with use of beta-blockers and angiotensin-converting
nzyme/angiotensin receptor blockers and age independently
redicted the primary end point. Past history of hypertension
ide (MR-proANP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in 60
al proatrial natriuretic peptide and NT-proBNP box plots. Median and interquartileic pept
regionr diabetes, Killip class, and eGFR were not predictors.
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May 13, 2008:1857–64 The LAMP StudyThe area under the receiver-operating characteristic curve
or MR-proANP (0.83 [95% CI 0.78 to 0.87]) and NT-
roBNP (0.83 [95% CI 0.78 to 0.87]) were similar. The AUC
Figure 2 Scatter Diagram
Spearman correlation between MR-proANP
and NT-proBNP, rs  0.63. Abbreviations as in Figure 1.
ox Regression Analysis for Death After AMI*
Table 2 Cox Regression Analysis for Death After AMI*
Univariate Analysis
Hazard Ratio
(95% CI) p V
Age 1.10 (1.08–1.12) 0
Male gender 0.47 (0.32–0.70) 0
Previous history of
AMI 2.52 (1.66–3.80) 0
Heart failure 1.64 (0.85–3.15) 0
Hypertension 1.57 (1.06–2.32) 0
Diabetes mellitus 1.74 (0.95–2.26) 0
Hypercholesterolemia 0.91 (0.57–1.48) 0
Smoking 0.69 (0.46–1.02) 0
Anterior AMI 1.01 (0.78–1.31) 0
ST-segment elevation AMI 1.06 (0.66–1.70) 0
Thrombolytic use 0.58 (0.39–0.86) 0
Killip class 1 2.50 (1.63–3.83) 0
Use of beta-blockers 0.29 (0.20–0.43) 0
Use of ACE/angiotensin receptor blockers 0.62 (0.41–0.92) 0
Log NT-proBNP 8.45 (5.35–13.35) 0
Log MR-proANP 22.54 (12.82–69.81) 0
eGFR 0.95 (0.94–0.96) 0
Peak CK 1.01 (0.97–1.03) 0
Ejection fraction 2.83 (1.89–4.22) 0Multivariate analysis results are reported for the whole group and for the subgroup with echocardiograp
ACE  angiotensin-converting enzyme; CI  confidence interval; CK  creatine kinase; NA  not applior troponin was 0.42 (95% CI 0.32 to 0.51, p  NS) and for
eak creatine kinase 0.40 (95% CI 0.29 to 0.50, p  NS).
For prediction of mortality, stratification by NT-proBNP
 or  median) correctly identified 83 end points, with an
dditional 10 identified using stratification by MR-proANP
 or  median). Using MR-proANP levels for risk
tratification, 87 end points were correctly identified, with
n additional 8 identified using stratification by NT-
roBNP. Thus, only 6 end points were incorrectly identified
sing both markers.
The Kaplan-Meier survival curves plotting quartiles of
R-proANP or NT-proBNP (Fig. 3) show that both
R-proANP and NT-proBNP are useful predictors of
eath post-AMI.
Patients in the top quartile for MR-proANP (above 331
mol/l) had a significantly higher mortality than those in
uartiles 1 to 3 (p  0.0001 for all). In patients stratified by
T-proBNP in the highest quartile (median 5,934 pmol/l),
R-proANP in the highest quartile gave additional infor-
ation on death in those patients who had NT-proBNP
evels above the highest quartile (log-rank test chi-square for
inear trend of factor levels pooled over NT-proBNP strata,
4.47, p  0.0001) (Fig. 4). Midregional proatrial natri-
retic peptide in the top quartile had predictive value in
hose patients in the lower 3 quartiles of NT-proBNP
log-rank test chi-square 39.28, p  0.0001). For NT-
roBNP in the lower 3 quartiles, those patients in the top
uartile of MR-proANP had higher event rates than those
Multivariate Analysis
(Whole Group)
Multivariate Analysis
(Echocardiography Subgroup)
Hazard Ratio
(95% CI) p Value
Hazard Ratio
(95% CI) p Value
1.04 (1.02–1.07) 0.002 1.05 (1.01–1.09) 0.009
0.69 (0.44–1.08) 0.11 0.75 (0.41–1.38) 0.35
1.44 (0.93–2.44) 0.10 1.02 (0.56–1.87) 0.94
NA NA NA NA
1.17 (0.77–1.77) 0.46 1.54 (0.87–2.72) 0.13
1.16 (0.73–1.85) 0.52 0.95 (0.50–1.82) 0.87
NA NA NA NA
1.19 (0.75–1.88) 0.46 1.01 (0.54–1.87) 0.99
NA NA NA NA
NA NA NA NA
1.11 (0.72–1.71) 0.63 1.04 (0.58–1.86) 0.91
0.93 (0.58–1.48) 0.75 1.44 (0.74–2.93) 0.32
0.44 (0.49–0.67) 0.001 0.46 (0.20–0.80) 0.006
0.63 (0.41–0.96) 0.034 0.77 (0.42–1.42) 0.40
3.25 (1.89–5.89) 0.0005 3.28 (1.49–7.25) 0.003
3.87 (1.51–9.93) 0.005 3.34 (1.03–10.84) 0.044
0.99 (0.98–1.01) 0.65 1.00 (0.98–1.02) 0.95
NA NA NA NA
1.99 (1.10–3.59) 0.023alue
.0005
.0005
.0005
.14
.024
.082
.716
.063
.93
.82
.007
.0005
.0005
.016
.0005
.0005
.0005
.87
.0005hy data (n  584).
cable; other abbreviations as in Table 1.
i
0
m
h
q
E
t
a
e
f
m
e
t
v
p
f
(
S
p
i
p
p
l
f
p
a
t
h
e
w
M
D
O
p
T
n
t
p
r
i
1862 Khan et al. JACC Vol. 51, No. 19, 2008
The LAMP Study May 13, 2008:1857–64n quartile 1 (p  0.0001), 2 (p  0.0001), and 3 (p 
.0004). Patients can, therefore, be classified into low- (both
arkers  lowest quartile), intermediate- (either marker 
ighest quartile), or high-risk (both markers  highest
uartile) groups (log-rank for trend, p  0.0005).
chocardiographic substudy. Echocardiographic parame-
ers were available for 584 subjects (59.4%) for the index
dmission. Plasma MR-proANP and NT-proBNP were
levated in patients with impaired left ventricular systolic
unction. In this subgroup, there were 54 deaths. Cox
odeling analysis of clinical and biomarker variables with
chocardiographic presence of impaired left ventricular sys-
olic function (biplanar ejection fraction as a continuous
ariable) revealed both biomarkers MR-proANP and NT-
Figure 3 Kaplan-Meier Survival Curves
Event rate (death) in patients grouped according to quartiles of plasma MR-
proANP or NT-proBNP (1  lowest quartile, 4  highest quartile). Abbreviations
as in Figure 1.roBNP along with use of beta-blockers, age, and ejectionraction as significant independent predictors of death
Table 2).
econdary end points: MR-proANP and NT-proBNP as
redictors of HF or recurrent myocardial infarction as
ndividual end points. Midregional proatrial natriuretic
eptide and NT-proBNP levels were significantly higher in
atients who were readmitted with HF compared with
evels in event-free survivors. Cox modeling revealed the
ollowing independent significant predictors: MR-proANP,
ast history of diabetes, and Killip class. Kaplan-Meier
nalysis revealed a lower readmission rate for HF in those in
he lower 3 quartiles of MR-proANP (p  0.0001) and the
ighest HF readmission rates in those with both biomarkers
levated in the highest quartile (p  0.0005).
Compared with survivors with no end points, patients
ho had recurrent AMI had similar NT-proBNP and
R-proANP levels.
iscussion
ur data indicated that NT-proBNP and MR-proANP are
owerful predictors of death after myocardial infarction.
he combination of markers from the A- and B-type
atriuretic peptide systems gives added prognostic informa-
ion above existing clinical characteristics, thus enabling
atients to be stratified into low-, intermediate-, or high-
isk groups.
Risk stratification at an early stage after AMI remains
mportant and may be useful in helping to select treatment
Figure 4 Combined Kaplan-Meier Survival Curve
Midregional proatrial natriuretic peptide levels (highest quartile vs. lower 3
quartiles) predicting the primary end point of death, in patients stratified by
NT-proBNP (highest quartile vs. lower 3 quartiles). Abbreviations as in Figure 1.
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May 13, 2008:1857–64 The LAMP Studyegimes in the future. Receiver-operator characteristic curve
nalysis indicated that NT-proBNP and MR-proANP were
f similar accuracy in prediction of death, more so than
arkers of structural myocardial damage such as troponin or
eak creatine kinase. Even though both markers are target-
ng the natriuretic hormone pathway, they are clearly giving
dditive and complementary information. Kaplan-Meier
nalysis revealed MR-proANP was useful irrespective of
hether NT-proBNP was high or low. A raised MR-
roANP and NT-proBNP in the highest quartile was
articularly useful in defining a high-risk group of patients.
ultimarker strategies for outcome after AMI using bio-
arkers that integrate different pathways have been utilized
efore (17). However, here we show that complementary
nformation can be gained by targeting different biomarkers
f the 2 natriuretic peptide neurohormonal systems.
The complementary information provided by MR-
roANP and NT-proBNP may partly be due to the
ifferent secretion patterns of both markers. There is a clear
ifference in secretion profile post-AMI of both markers,
ith MR-proANP peaking on Day 1 as compared with the
T-proBNP peak by Day 2. Also, NT-proBNP levels
ppear to be more dependent on renal function than
R-proBNP levels. Patients with markedly raised MR-
roBNP but low NT-proBNP levels had significantly
reater eGFR values and vice versa; this, however, did not
ave an impact on outcomes. These are the only identifiable
ifferences between the 2 markers, similarities between the
being elevated levels in female patients compared with
evels in male patients and a strong correlation with eGFR
a surrogate marker of renal function) and left ventricular
ystolic dysfunction. In the subset with echocardiography
ata, both biomarkers remained independent predictors of
oor outcome. Our data are consistent with previous anal-
ses (e.g., with ejection fraction and a single marker NT-
roBNP) (6), which have retained imaging parameters in
redicting similar outcomes. Midregional proatrial natri-
retic peptide has been investigated in patients after an
MI where it has also been shown to be comparable to
T-proBNP for the detection of impaired left ventricular
unction (18). This study, unlike ours, is a small investiga-
ion in post-AMI patients at a remote time point after the
cute event (mean follow-up 687 days).
The benefits of measuring both prohormones over their
ioactive peptides include the lack of receptor binding or
rotein interactions and the longer half-lives resulting in
igher plasma levels. The prohormones are also more stable
n blood ex vivo, and this makes them generally more
pplicable in clinical practice (11). Previous studies with
NP or NT-proANP have not revealed independent pre-
ictive value of the A-type over the B-type natriuretic
eptide systems (5,9). This is in contrast to what we have
ound, and this could be attributed to performance of
ifferent assays. In particular, assays directed to the N- and
-terminals of proANP may be more susceptible to endog-nous proteases, providing the rationale for measuringidregional epitopes in the current MR-proANP assay
11). There is evidence of much heterogeneity in molecular
orms of both NT-proBNP and NT-proANP, with evi-
ence that midregional epitopes may be relatively preserved
n plasma samples (19).
Natriuretic peptides in the post-AMI period probably
ave a beneficial effect, causing vasodilatation and increas-
ng diuresis at a time when the ventricle has sustained a
ignificant insult. The current findings confirm previous
tudies about the benefits of measuring the natriuretic
eptides after an AMI and suggest that a combination
arker approach may be more specific at identifying a
igher risk group of patients associated with poor outcome
fter AMI.
tudy limitations. There are some limitations that should
e mentioned. This was a single-center study with a
reponderance of relatively higher risk ST-segment eleva-
ion AMI patients, so that cut-points for non–ST-segment
levation AMI may need to be independently established.
lthough we used very minimal exclusion criteria, there was
disproportionately higher number of STEMI than
STEMI. This may, in part, be due to the admission
olicies that naturally exist where patients with STEMI are
ore likely to be admitted to a coronary care unit than
atients with NSTEMI. Our study employed blood samples
n the recovery phase of AMI, and the utility of initial triage
lood samples should be investigated. Finally, although
oth markers predicted 95 of the 101 events, 6 remaining
vents eluded prediction.
onclusions
his is the first report showing MR-proANP to be a new
rognostic marker of death in patients with AMI, indepen-
ent of established conventional risk factors. A multimarker
pproach with MR-proANP and NT-proBNP targeting
oth the A- and B-type natriuretic neurohormonal path-
ays is more informative than either marker alone and may
e useful for risk stratification in AMI patients.
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